S. Bartholomeus

3.0k total citations
17 papers, 670 citations indexed

About

S. Bartholomeus is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, S. Bartholomeus has authored 17 papers receiving a total of 670 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Cancer Research and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in S. Bartholomeus's work include Cancer Treatment and Pharmacology (8 papers), Breast Cancer Treatment Studies (4 papers) and HER2/EGFR in Cancer Research (3 papers). S. Bartholomeus is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Breast Cancer Treatment Studies (4 papers) and HER2/EGFR in Cancer Research (3 papers). S. Bartholomeus collaborates with scholars based in Belgium, Germany and United States. S. Bartholomeus's co-authors include Ahmad Awada, Thierry Gil, Martine Piccart, Dominique de Valeriola, E. Brendel, Alain Hendlisz, Catherine G. Haase, Dirk Strumberg, Brian Schwartz and Max S. Mano and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

S. Bartholomeus

17 papers receiving 653 citations

Peers

Countries citing papers authored by S. Bartholomeus

Since Specialization

Citations

This map shows the geographic impact of S. Bartholomeus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Bartholomeus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Bartholomeus more than expected).

Fields of papers citing papers by S. Bartholomeus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Bartholomeus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Bartholomeus. The network helps show where S. Bartholomeus may publish in the future.

Co-authorship network of co-authors of S. Bartholomeus

This figure shows the co-authorship network connecting the top 25 collaborators of S. Bartholomeus. A scholar is included among the top collaborators of S. Bartholomeus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Bartholomeus. S. Bartholomeus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity 2015 ·Investigational New Drugs ·Ahmad Awada, Herlinde Dumez, Philippe Aftimos, (unknown), S. Bartholomeus, (unknown), Thierry Berghmans, (unknown), (unknown), Gerd Munzert, Korinna Pilz, Dan Liu, Patrick Schöffski	20
2	Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours 2012 ·European Journal of Cancer ·Ahmad Awada, Alain Hendlisz, Olaf Christensen, Chetan Lathia, S. Bartholomeus, Fabienne Lebrun, Dominique de Valeriola, E. Brendel, Martin Radtke, Thierry Delaunoit, Martine Piccart, Thierry Gil	20
3	A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours 2011 ·European Journal of Cancer ·Patrick Schöffski, Ahmad Awada, Herlinde Dumez, Thierry Gil, S. Bartholomeus, Pascal Wolter, M. Taton, Holger Fritsch, (unknown), Gerd Munzert	132
4	Final analysis of a phase I single dose-escalation study of the novel polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumors. 2010 ·Journal of Clinical Oncology ·(unknown), P. Schöffski, Ahmad Awada, Herlinde Dumez, S. Bartholomeus, (unknown), M. Taton, Holger Fritsch, (unknown), Gerd Munzert	6
5	36 ORAL A Phase I single dose escalation study of the novel Polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumours 2008 ·European Journal of Cancer Supplements ·Patrick Schöffski, Ahmad Awada, Herlinde Dumez, (unknown), S. Bartholomeus, (unknown), M. Taton, Holger Fritsch, N. Peter, Gerd Munzert	8
6	A phase I, open label, dose-escalating study of the proteasome inhibitor PS-341 (VELCADE¢) in combination with two schedules of trastuzumab, in patients with advanced breast cancer (ABC) that overexpresses HER-2 2006 ·European Journal of Cancer Supplements ·Fátima Cardoso, Evandro de Azambuja, C. Bernard, Luc Dirix, (unknown), S. Bartholomeus, (unknown), Helgi van de Velde, Martine Piccart, Ahmad Awada	2
7	Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours 2005 ·British Journal of Cancer ·Ahmad Awada, Alain Hendlisz, Thierry Gil, S. Bartholomeus, Max S. Mano, Dominique de Valeriola, Dirk Strumberg, E. Brendel, Catherine G. Haase, Brian Schwartz, Martine Piccart	272
8	A phase I study of BAY 43-9006, a novel Raf kinase and VEGFR inhibitor, in combination with taxotere in patients with advanced, solid tumors 2004 ·European Journal of Cancer ·Ahmad Awada, Alain Hendlisz, Thierry Gil, Bertrand Schwartz, S. Bartholomeus, Dominique de Valeriola, E. Brendel, Claus G. Haase, Martine Piccart	4
9	381 A phase I study of BAY 43-90006, a novel Raf kinase and VEGFR inhibitor, in combination with taxotere in patients with advanced solid tumors 2004 ·European Journal of Cancer Supplements ·Ahmad Awada, Alain Hendlisz, Thierry Gil, B. Schwartz, S. Bartholomeus, E. Brendel, Dominique de Valeriola, Catherine G. Haase, Thierry Delaunoit, M. Piccart	7
10	The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutions 2002 ·Annals of Oncology ·(unknown), Angelo Di Leo, Marianne Paesmans, M. Beauduin, A. Vindevoghel, (unknown), C Focan, Ahmad Awada, Fátima Cardoso, Stella Dolci, S. Bartholomeus, Martine Piccart	5
11	Phase III Trial Comparing Two Dose Levels of Epirubicin Combined With Cyclophosphamide With Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer 2001 ·Journal of Clinical Oncology ·Martine Piccart, Angelo Di Leo, M. Beauduin, A. Vindevoghel, (unknown), C. Focan, (unknown), F. Ries, (unknown), (unknown), (unknown), (unknown), Joseph Kerger, (unknown), Sylvie Beauvois, S. Bartholomeus, Stella Dolci, J.P. Lobelle, Marianne Paesmans, J.-M. Nogaret	119
12	A clinical, pharmacokinetic and pharmacodynamic phase I study of the raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors 2001 ·Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) ·Ahmad Awada, Alain Hendlisz, Thierry Gil, Harry Bleiberg, S. Bartholomeus, Dominique de Valeriola, (unknown), Sabine Coppieters, J Moeller, (unknown), Anne‐Pascale Meert, Martine Piccart	3
13	A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer 2000 ·Annals of Oncology ·Angelo Di Leo, John Crown, Jean‐Marie Nogaret, (unknown), S. Bartholomeus, Stella Dolci, Susan Rowan, N. J. O’Higgins, Marianne Paesmans, Denis Larsimont, A. Riva, Martine Piccart	18
14	A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors. 2000 ·PubMed ·Eric Van Den Neste, Dominique de Valeriola, Joseph Kerger, Harry Bleiberg, (unknown), Christiane Brassinne, S. Bartholomeus, J. Selleslags, (unknown), (unknown), (unknown), (unknown), Martine Piccart	25
15	Doxorubicin (A) followed by docetaxel (T) versus doxorubicin + docetaxel (AT) in the adjuvant treatment of breast cancer (BC) 1998 ·European Journal of Cancer ·Angelo Di Leo, John Crown, (unknown), (unknown), S. Bartholomeus, Stella Dolci, Susan Rowan, N. J. O’Higgins, A. Riva, Martine Piccart	1
16	Clinical and pharmacokinetic (PK) phase I study of Docetaxel (TXT) combined to continuous infusion (CI) of 5-Fluoroucil (FU) in advanced cancer patients 1997 ·Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) ·Dominique de Valeriola, (unknown), Joseph Kerger, S. Bartholomeus, (unknown), Eric Van Den Neste, Martine Piccart	2
17	An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer 1995 ·Annals of Oncology ·Martine Piccart, P.F. Bruning, J. Wildiers, Ahmad Awada, Jan H. Schornagel, José Thomas, Eva Tomiak, S. Bartholomeus, (unknown), Robert Paridaens	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact